Advances in Antiplatelet Therapy for Dentofacial Surgery Patients: Focus on Past and Present Strategies.
Gabriele CervinoLuca FiorilloInes Paola MonteRosa De StefanoLuigi LainoSalvatore CrimiAlberto BianchiAlan Scott HerfordAntonio BiondiMarco Cicciu'Published in: Materials (Basel, Switzerland) (2019)
Either patients take these medications for different reasons, because of cardiovascular pathologies, recent cardiovascular events, or even for simple prevention, although the latest research shows that there is no decrease of cardiovascular accidents in patients who carry out preventive therapy. Surely, it will be at the expense of the doctor to assess the patient's situation and risk according to the guidelines. For simple oral surgery, it is not necessary to stop therapy with antiplatelet agents because the risk of bleeding has not increased, and is localized to a post-extraction alveolus or to an implant preparation, compared to patients who do not carry out this therapy. From an analysis of the results it emerges that the substitutive therapy should no longer be performed and that it is possible to perform oral surgery safely in patients who take antiplatelet drugs, after a thorough medical history. Furthermore, by suspending therapy, we expose our patients to more serious risks, concerning their main pathology, where present.
Keyphrases
- end stage renal disease
- cardiovascular events
- ejection fraction
- minimally invasive
- chronic kidney disease
- prognostic factors
- peritoneal dialysis
- antiplatelet therapy
- coronary artery disease
- cardiovascular disease
- coronary artery bypass
- stem cells
- percutaneous coronary intervention
- atrial fibrillation
- mass spectrometry
- climate change
- smoking cessation